Advertisement

European Journal of Clinical Pharmacology

, Volume 70, Issue 10, pp 1251–1260 | Cite as

Feasibility of discontinuing chronic benzodiazepine use in nursing home residents: a pilot study

  • Jolyce BourgeoisEmail author
  • Monique M. Elseviers
  • Luc Van Bortel
  • Mirko Petrovic
  • Robert H. Vander Stichele
Pharmacoepidemiology and Prescription

Abstract

Purpose

Guidelines discourage chronic benzodiazepines and related Z drugs (BZD/Zs) for sleep problems. However, prevalence among nursing home residents remains high. Discontinuing these drugs is widely recommended but seems difficult to implement. The aim of our study was to evaluate the overall feasibility in the nursing home, in terms of willingness towards discontinuation and success rate at 8 months, together with the impact on withdrawal symptoms, change in sleep quality, quality of life and medication use.

Methods

In a convenience sample of five nursing homes (823 residents), we included cognitively competent residents with chronic BZD/Z use for insomnia. We investigated sleep quality [with Pittsburgh Sleep Quality Index (PSQI)], quality of life (EQ-5D) and withdrawal symptoms [Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ)]. Success rate was analysed with survival analysis.

Results

Of the 135 eligible residents, both general physician (GP) and resident were willing to initiate discontinuation in 38 residents. Reasons for refusing to initiate discontinuation among GPs was the unmotivated patient and among residents the reluctance towards change. At 8 months, 66.0 % were successful discontinuers, with the subjective PSQI component evolving favourably (p = 0.013) and a decreasing number of midnight awakenings (p = 0.041). In the relapse group (n = 13), the quality of life decreased (p = 0.012), with mainly an increase of problems with activities and pain/discomfort. In both groups, the withdrawal symptoms, functionality and medication use did not change.

Conclusion

Discontinuation of chronic BZD/Z use is feasible in the nursing home setting without noticeable withdrawal symptoms, without a switch in medication use, without detrimental effect on quality of life and with a positive effect on the self-perceived sleep quality.

Keywords

Benzodiazepine Nursing homes Sleep problems Discontinuation 

Notes

Acknowledgments

We thank all participating nursing homes, the general physicians and, especially, the head nurses for their collaboration.

Contribution of authors

J. Bourgeois formulated the research question, did the date collection, performed analyses and wrote the paper.

M. Elseviers formulated the research question, did the supervision of the statistical analyses and assisted with writing the paper.

M. Petrovic assisted with writing the paper and gave input from a clinical geriatric point of view.

L. Van Bortel assisted with writing the paper.

R. Vander Stichele formulated the research question, assisted with writing the paper and helped interpret the results.

References

  1. 1.
    Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE (2005) Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 331(7526):1169. doi: 10.1136/bmj.38623.768588.47 PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    2 McIntosh B, Clark M, Spry C. (2011) Benzodiazepines in older adults: a review of clinical effectiveness, cost-effectiveness, and guidelines. Rapid response report: peer-reviewed summary with critical appraisal. Canadian Agency for Drugs and Technologies in Health, OttawaGoogle Scholar
  3. 3.
    Ashton H (1994) Guidelines for the rational use of benzodiazepines—when and what to use. Drugs 48(1):25–40CrossRefPubMedGoogle Scholar
  4. 4.
    Bloom HG, Ahmed I, Alessi CA, Ancoli-Israel S, Buysse DJ, Kryger MH, Phillips BA, Thorpy MJ, Vitiello MV, Zee PC (2009) Evidence-based recommendations for the assessment and management of sleep disorders in older persons. J Am Geriatr Soc 57(5):761–789PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Committee on Safety of Medicines (1988) UK Government Bulletin to Prescribing Doctors: benzodiazepines, dependence and withdrawal symptomsGoogle Scholar
  6. 6.
    Turnham H. (2001) Federal Nursing Home Reform Act from the Omnibus Budget Reconciliation Act of 1987. National Long Term Care Ombudsman Resource CenterGoogle Scholar
  7. 7.
    (2011) The impact of psychotropics on health with special attention to the elderly. Belgium Superior Health CouncilGoogle Scholar
  8. 8.
    Bourgeois J, Elseviers MM, Van Bortel L, Petrovic M, Vander Stichele RH (2013) Sleep quality of benzodiazepine users in nursing homes: a comparative study with nonusers. Sleep Med 14(7):614–621. doi: 10.1016/j.sleep.2013.03.012 CrossRefPubMedGoogle Scholar
  9. 9.
    Hosia-Randell H, Pitkala K (2005) Use of psychotropic drugs in elderly nursing home residents with and without dementia in Helsinki, Finland. Drugs Aging 22(9):793–800CrossRefPubMedGoogle Scholar
  10. 10.
    Gobert M, D’Hoore W (2005) Prevalence of psychotropic drug use in nursing homes for the aged in Quebec and in the French-speaking area of Switzerland. Int J Geriatr Psychiatry 20(8):712–721. doi: 10.1002/gps.1349 CrossRefPubMedGoogle Scholar
  11. 11.
    de Souto Barreto P, Lapeyre-Mestre M, Mathieu C, Piau C, Bouget C, Cayla F, Vellas B, Rolland Y (2013) Indicators of benzodiazepine use in nursing home residents in France: a cross-sectional study. J Am Med Dir Assoc 14(1):29–33. doi: 10.1016/j.jamda.2012.09.002 CrossRefPubMedGoogle Scholar
  12. 12.
    Lader M, Tylee A, Donoghue J (2009) Withdrawing benzodiazepines in primary care. CNS Drugs 23(1):19–34. doi: 10.2165/0023210-200923010-000022312 CrossRefPubMedGoogle Scholar
  13. 13.
    Ostini R, Jackson C, Hegney D, Tett SE (2011) How is medication prescribing ceased? A systematic review. Med Care 49(1):24–36. doi: 10.1097/MLR.0b013e3181ef9a7e CrossRefPubMedGoogle Scholar
  14. 14.
    Voshaar RC, Couvee JE, van Balkom AJ, Mulder PG, Zitman FG (2006) Strategies for discontinuing long-term benzodiazepine use: meta-analysis. Br J Psychiatry 189:213–220. doi: 10.1192/bjp.189.3.213 CrossRefPubMedGoogle Scholar
  15. 15.
    Rickels K, Schweizer E, Case WG, Greenblatt DJ (1990) Long-term therapeutic use of benzodiazepines. I Effects of abrupt discontinuation. Arch Gen Psychiatry 47(10):899–907CrossRefPubMedGoogle Scholar
  16. 16.
    Petrovic M, Pevernagie D, Van Den Noortgate N, Mariman A, Michielsen W, Afschrift M (1999) A programme for short-term withdrawal from benzodiazepines in geriatric hospital inpatients: success rate and effect on subjective sleep quality. Int J Geriatr Psychiatry 14(9):754–760. doi: 10.1002/(SICI)1099-1166(199909)14:9<754::AID-GPS15>3.0.CO;2-E CrossRefPubMedGoogle Scholar
  17. 17.
    Ashton H (1987) Benzodiazepine withdrawal: outcome in 50 patients. Br J Addict 82(6):665–671CrossRefPubMedGoogle Scholar
  18. 18.
    Gould RL, Coulson MC, Patel N, Highton-Williamson E, Howard RJ (2014) Interventions for reducing benzodiazepine use in older people: meta-analysis of randomised controlled trials. Br J Psychiatry 204(2):98–107. doi: 10.1192/bjp.bp.113.126003 CrossRefPubMedGoogle Scholar
  19. 19.
    Salonoja M, Salminen M, Aarnio P, Vahlberg T, Kivela SL (2010) One-time counselling decreases the use of benzodiazepines and related drugs among community-dwelling older persons. Age Ageing 39(3):313–319. doi: 10.1093/ageing/afp255 CrossRefPubMedGoogle Scholar
  20. 20.
    Petrovic M, Pevernagie D, Mariman A, Van Maele G, Afschrift M (2002) Fast withdrawal from benzodiazepines in geriatric inpatients: a randomised double-blind, placebo-controlled trial. Eur J Clin Pharmacol 57(11):759–764CrossRefPubMedGoogle Scholar
  21. 21.
    Tham TC, Brown H, Taggart HM (1989) Temazepam withdrawal in elderly hospitalized patients: a double blind randomised trial comparing abrupt versus gradual withdrawal. Ir J Med Sci 158(12):294–299CrossRefPubMedGoogle Scholar
  22. 22.
    Avorn J, Soumerai SB, Everitt DE, Ross-Degnan D, Beers MH, Sherman D, Salem-Schatz SR, Fields D (1992) A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes. N Engl J Med 327(3):168–173. doi: 10.1056/NEJM199207163270306 CrossRefPubMedGoogle Scholar
  23. 23.
    Habraken H, Soenen K, Blondeel L, VanElsen J, Bourda J, Coppens E, Willeput M (1997) Gradual withdrawal from benzodiazepines in residents of homes for the elderly: experience and suggestions for future research. Eur J Clin Pharmacol 51(5):355–358CrossRefPubMedGoogle Scholar
  24. 24.
    Bell JS, Lavikainen P, Korhonen M, Hartikainen S (2011) Benzodiazepine discontinuation among community-dwelling older people: a population-based cohort study. Eur J Clin Pharmacol 67(1):105–106. doi: 10.1007/s00228-010-0897-z CrossRefPubMedGoogle Scholar
  25. 25.
    Tsunoda K, Uchida H, Suzuki T, Watanabe K, Yamashima T, Kashima H (2010) Effects of discontinuing benzodiazepine-derivative hypnotics on postural sway and cognitive functions in the elderly. Int J Geriatr Psychiatry 25(12):1259–1265. doi: 10.1002/gps.2465 CrossRefPubMedGoogle Scholar
  26. 26.
    Gilbert A, Owen N, Innes JM, Sansom L (1993) Trial of an intervention to reduce chronic benzodiazepine use among residents of aged-care accommodation. Aust N Z J Med 23(4):343–347CrossRefPubMedGoogle Scholar
  27. 27.
    Salzman C, Fisher J, Nobel K, Glassman R, Wolfson A, Kelley M (1992) Cognitive improvement following benzodiazepine discontinuation in elderly nursing-home residents. Int J Geriatr Psychiatry 7(2):89–93CrossRefGoogle Scholar
  28. 28.
    Elseviers MM, Vander Stichele RR, Van Bortel L (2010) Drug utilization in Belgian nursing homes: impact of residents’ and institutional characteristics. Pharmacoepidemiol Drug Saf 19(10):1041–1048. doi: 10.1002/pds.1983 CrossRefPubMedGoogle Scholar
  29. 29.
    Katz S, Akpom CA (1976) 12. Index of ADL. Med Care 14(5 Suppl):116–118CrossRefPubMedGoogle Scholar
  30. 30.
    WHO (2009) ATC/DDD system. WHO Collaborating Centre for Drug Statistics MethodologyGoogle Scholar
  31. 31.
    Ashton CH (2007) Benzodiazepine equivalence tableGoogle Scholar
  32. 32.
    Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO (1982) Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 17(1):37–49CrossRefPubMedGoogle Scholar
  33. 33.
    Smalbrugge M, Jongenelis L, Pot AM, Beekman AT, Eefsting JA (2008) Screening for depression and assessing change in severity of depression. Is the Geriatric Depression Scale (30-, 15- and 8-item versions) useful for both purposes in nursing home patients? Aging & Mental Health 12(2):244–248. doi: 10.1080/13607860801987238 CrossRefGoogle Scholar
  34. 34.
    Jongenelis K, Gerritsen DL, Pot AM, Beekman ATF, Eisses AMH, Kluiter H, Ribbe MW (2007) Construction and validation of a patient- and user-friendly nursing home version of the Geriatric Depression Scale. Int J Geriatr Psychiatry 22(9):837–842. doi: 10.1002/Gps.1748 CrossRefPubMedGoogle Scholar
  35. 35.
    Tyrer P, Murphy S, Riley P (1990) The Benzodiazepine Withdrawal Symptom Questionnaire. J Affect Disord 19(1):53–61CrossRefPubMedGoogle Scholar
  36. 36.
    Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28(2):193–213CrossRefPubMedGoogle Scholar
  37. 37.
    Verster JC, David B, Morgan K, Olivier B (2008) Validation of the Dutch Occupational Impact of Sleep Questionnaire (OISQ). Ind Health 46(6):601–606CrossRefPubMedGoogle Scholar
  38. 38.
    Rabin R, de Charro F (2001) EQ-5D: a measure of health status from the EuroQol Group. Ann Med 33(5):337–343CrossRefPubMedGoogle Scholar
  39. 39.
    Al Aqqad SM, Chen LL, Shafie AA, Hassali MA, Tangiisuran B (2014) The use of potentially inappropriate medications and changes in quality of life among older nursing home residents. Clin Interv Aging 9:201–207. doi: 10.2147/CIA.S52356 PubMedGoogle Scholar
  40. 40.
    Dolan P, Gudex C, Kind P, Williams A (1996) The time trade-off method: results from a general population study. Health Econ 5(2):141–154. doi: 10.1002/(SICI)1099-1050(199603)5:2<141::AID-HEC189>3.0.CO;2-N CrossRefPubMedGoogle Scholar
  41. 41.
    Holmes HM, Luo R, Kuo YF, Baillargeon J, Goodwin JS (2013) Association of potentially inappropriate medication use with patient and prescriber characteristics in Medicare Part D. Pharmacoepidemiol Drug Saf 22(7):728–734. doi: 10.1002/pds.3431 PubMedCentralCrossRefPubMedGoogle Scholar
  42. 42.
    Gorgels W, Oude Voshaar R, Mol A, van de Lisdonk E, van den Hoogen H, van Balkom A, Breteler M, Zitman F (2008) General practitioners’ opinions of a stepped-care benzodiazepine discontinuation programme. Eur J Gen Pract 14(1):37–39. doi: 10.1080/13814780701855666 CrossRefPubMedGoogle Scholar
  43. 43.
    Cook JM, Marshall R, Masci C, Coyne JC (2007) Physicians’ perspectives on prescribing benzodiazepines for older adults: a qualitative study. J Gen Intern Med 22(3):303–307. doi: 10.1007/s11606-006-0021-3 PubMedCentralCrossRefPubMedGoogle Scholar
  44. 44.
    Siriwardena AN, Qureshi Z, Gibson S, Collier S, Latham M (2006) GPs’ attitudes to benzodiazepine and ‘Z-drug’ prescribing: a barrier to implementation of evidence and guidance on hypnotics. Br J Gen Pract 56(533):964–967PubMedCentralPubMedGoogle Scholar
  45. 45.
    Iliffe S, Curran HV, Collins R, Kee SCY, Fletcher S, Woods B (2004) Attitudes to long-term use of benzodiazepine hypnotics by older people in general practice: findings from interviews with service users and providers. Aging & Mental Health 8(3):242–248. doi: 10.1080/13607860410001669778 CrossRefGoogle Scholar
  46. 46.
    van Hulten R, Bakker AB, Lodder AC, Teeuw KB, Bakker A, Leufkens HG (2003) The impact of attitudes and beliefs on length of benzodiazepine use: a study among inexperienced and experienced benzodiazepine users. Soc Sci Med 56(6):1345–1354CrossRefPubMedGoogle Scholar
  47. 47.
    Anthierens S, Habraken H, Petrovic M, Deveugele M, De Maeseneer J, Christiaens T (2007) First benzodiazepine prescriptions: qualitative study of patients’ perspectives. Can Fam Physician 53(7):1200–1201PubMedCentralPubMedGoogle Scholar
  48. 48.
    Tsunoda K, Tanabe A, Uchida H, Suzuki T, Tomita M, Yamashima T, Watanabe K, Kashima H (2008) Effects of discontinuing benzodiazepine-derivative hypnotics on cognitive and motor functions in the elderly: A pilot study. Int J Neuropsychopharmacol 11:301–301Google Scholar
  49. 49.
    Vicens C, Socias I, Mateu C, Leiva A, Bejarano F, Sempere E, Basora J, Palop V, Mengual M, Beltran JL, Aragones E, Lera G, Folch S, Pinol JL, Esteva M, Roca M, Arenas A, Del Mar SM, Campoamor F, Fiol F (2011) Comparative efficacy of two primary care interventions to assist withdrawal from long term benzodiazepine use: a protocol for a clustered, randomized clinical trial. BMC Fam Pract 12:23. doi: 10.1186/1471-2296-12-23 PubMedCentralCrossRefPubMedGoogle Scholar
  50. 50.
    Parsons C, Hughes CM, Passmore AP, Lapane KL (2010) Withholding, discontinuing and withdrawing medications in dementia patients at the end of life: a neglected problem in the disadvantaged dying? Drugs Aging 27(6):435–449. doi: 10.2165/11536760-000000000-00000 CrossRefPubMedGoogle Scholar
  51. 51.
    Bourgeois JEM, Azermai M, Van Bortel L, Petrovic M, Vander SR (2014) Barriers to discontinuation of chronic benzodiazepine use in nursing home residents: perceptions of general practitioners and nurses. Eur Geriatr Med 5(3):181–187CrossRefGoogle Scholar
  52. 52.
    Baldwin D, Woods R, Lawson R, Taylor D (2011) Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ 342:d1199. doi: 10.1136/bmj.d1199 CrossRefPubMedGoogle Scholar
  53. 53.
    Curran HV, Collins R, Fletcher S, Chin YKS, Woods RT, Iliffe S (2003) Withdrawal of older adults from benzodiazepine hypnotics in general practice: effects on cognitive function, sleep, mood and quality of life. J Psychopharmacol 17(3):A26–A26Google Scholar
  54. 54.
    Linden M, Bar T, Geiselmann B (1998) Patient treatment insistence and medication craving in long-term low-dosage benzodiazepine prescriptions. Psychol Med 28(3):721–729CrossRefPubMedGoogle Scholar
  55. 55.
    Parr JM, Kavanagh DJ, Young RM, McCafferty K (2006) Views of general practitioners and benzodiazepine users on benzodiazepines: a qualitative analysis. Soc Sci Med 62(5):1237–1249. doi: 10.1016/j.socscimed.2005.07.016 CrossRefPubMedGoogle Scholar
  56. 56.
    Dyas JV, Apekey TA, Tilling M, Orner R, Middleton H, Siriwardena AN (2010) Patients’ and clinicians’ experiences of consultations in primary care for sleep problems and insomnia: a focus group study. Br J Gen Pract 60(574):e180–200. doi: 10.3399/bjgp10X484183 PubMedCentralCrossRefPubMedGoogle Scholar
  57. 57.
    Parr JM, Kavanagh DJ, Cahill L, Mitchell G, Mc DYR (2009) Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta-analysis. Addiction 104(1):13–24. doi: 10.1111/j.1360-0443.2008.02364.x CrossRefPubMedGoogle Scholar
  58. 58.
    Soldatos CR, Dikeos DG, Whitehead A (1999) Tolerance and rebound insomnia with rapidly eliminated hypnotics: a meta-analysis of sleep laboratory studies. Int Clin Psychopharmacol 14(5):287–303CrossRefPubMedGoogle Scholar
  59. 59.
    Wolkove N, Elkholy O, Baltzan M, Palayew M (2007) Sleep and aging: 2. Management of sleep disorders in older people. Cmaj 176(10):1449–1454. doi: 10.1503/cmaj.070335 PubMedCentralCrossRefPubMedGoogle Scholar
  60. 60.
    Ong MK, Xu H, Zhang L, Azocar F, Ettner SL (2012) Effect of medicare part D benzodiazepine exclusion on psychotropic use in benzodiazepine users. J Am Geriatr Soc 60(7):1292–1297. doi: 10.1111/j.1532-5415.2012.04031.x CrossRefPubMedGoogle Scholar
  61. 61.
    Weintraub M, Singh S, Byrne L, Maharaj K, Guttmacher L (1991) Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations. JAMA 266(17):2392–2397CrossRefPubMedGoogle Scholar
  62. 62.
    Zullich SG, Grasela TH Jr, Fiedler-Kelly JB, Gengo FM (1992) Impact of triplicate prescription program on psychotropic prescribing patterns in long-term care facilities. Ann Pharmacother 26(4):539–546PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Jolyce Bourgeois
    • 1
    Email author
  • Monique M. Elseviers
    • 1
    • 2
  • Luc Van Bortel
    • 1
  • Mirko Petrovic
    • 1
    • 3
  • Robert H. Vander Stichele
    • 1
  1. 1.Heymans Institute of PharmacologyGhent UniversityGhentBelgium
  2. 2.Department of Nursing ScienceUniversity of AntwerpAntwerpBelgium
  3. 3.Department of GeriatricsGhent University HospitalGhentBelgium

Personalised recommendations